Sangamo Biosciences reported $-53155000 in Net Income for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
Alnylam Pharmaceuticals ALNY:US USD -405920000 128.52M
Amgen AMGN:US USD 2.14B 826M
Bayer BAYN:GR EUR 546M 844M
Biocryst Pharmaceuticals BCRX:US USD -42520000 16.34M
Biogen BIIB:US USD 1.13B 76.7M
Biomarin Pharmaceutical BMRN:US USD -6652000 34.32M
Bluebird Bio BLUE:US USD -76520000 23.62M
Gilead Sciences GILD:US USD 1.79B 645M
GlaxoSmithKline GSK:LN GBP 10.32B 9.48B
Intercept Pharmaceuticals ICPT:US USD 267.45M 274.98M
IONIS PHARMACEUT IONS:US USD -46992000 58.14M
Johnson & Johnson JNJ:US USD 3.52B 938M
Karyopharm Therapeutics KPTI:US USD -36324000 12.74M
Merk MRK:US USD 3.25B 696M
Novartis NOVN:VX USD 1.57B 121M
Omeros OMER:US USD -17456000 13.39M
Pfizer PFE:US USD 8.61B 1.3B
Regulus Therapeutics RGLS:US USD -7551000 293K
Roche Holding ROG:VX 8.53B 2.4B
Sangamo Biosciences SGMO:US USD -53155000 9.98M
Sarepta Therapeutics SRPT:US USD -257738000 26.26M
Ultragenyx Pharmaceutical RARE:US USD -245106000 86.94M
Vertex Pharmaceuticals VRTX:US USD 930.5M 120M